Carregant...
The evolution of biosimilars in oncology, with a focus on trastuzumab
Cancer therapy has evolved significantly with increased adoption of biologic agents (“biologics”). That evolution is especially true for her2 (human epidermal growth factor receptor-2)–positive breast cancer with the introduction of trastuzumab, a monoclonal antibody against the her2 receptor, which...
Guardat en:
| Publicat a: | Curr Oncol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Multimed Inc.
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6001768/ https://ncbi.nlm.nih.gov/pubmed/29910660 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.25.3942 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|